Loading…
← CockpitCompetitor Analysis › 688298.SS Zhejiang Orient Gene Biotech Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Orient Gene Biotech Co., Ltd. Class A688298.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum neutral 50
Mkt cap
$500M
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$7.46M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-16.0 pp
WACC 7.9%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥16.67
1D-1.6%
1W-8.3%
1M-8.0%
3M-15.3%
6M-27.2%
YTD-28.9%
1Y-36.5%
ATR %4.8%
52w lowhigh42.5% off high

What Zhejiang Orient Gene Biotech does

Employees: 2,283

Zhejiang Orient Gene Biotech at a glance

Size Zhejiang Orient Gene Biotech (688298.SS) is a China Health Care company (Medical Specialties) with a market value of $500M, the 3703rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥16.67 on 18 Nov 2026.

Performance Over six months the shares fell 27.2%, against -16.1% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 17.9% over the last twelve months (peer median +5.4%); the operating margin is -59.9% (peer median 3.5%).

Valuation It trades at 1.6× enterprise value to sales against a peer median of 2.7× (7th cheapest of 19).

Capital Return on invested capital runs 16.0 points below its cost of capital (7.9% WACC).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 84688298.SS 73
Six months, rebased to 100: Zhejiang Orient Gene Biotech against the median of its 20 peers (local-currency closes).

Zhejiang Orient Gene Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥993MCN¥945MCN¥827MCN¥819MCN¥8.70B
Revenue growth—+14%+1%-91%—
Gross profitCN¥448MCN¥206MCN¥74.3MCN¥195MCN¥4.34B
EBITDAn/a-CN¥272M-CN¥535M-CN¥475MCN¥1.99B
Net income-CN¥658M-CN¥574M-CN¥529M-CN¥398MCN¥2.07B
Free cash flow-CN¥384M-CN¥492M-CN¥1.24B-CN¥2.60BCN¥1.96B
Capital expenditureCN¥269MCN¥308MCN¥924MCN¥996MCN¥1.05B
Total debtCN¥478MCN¥397MCN¥593MCN¥697MCN¥600M

Quarterly statements and history in the cockpit →

Zhejiang Orient Gene Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%688580MEDX688075AVR6035207979300639002932688606NNNN300439CEVIANGO603309RCELMYGNZJYL688298.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Orient Gene Biotech is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%0×50×100×688580MEDX688075AVR603520688606300439301033CEVIRCELMYGNZJYL688298.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Orient Gene Biotech is the large dot.

Zhejiang Orient Gene Biotech competitors and peer comparison

How Zhejiang Orient Gene Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Orient Gene Biotech against its 20 peers (data as of 18 Nov 2026)
Measure688298.SSPeer medianRank in peer set
1-month return-8.0%-3.8%7th lowest of 21
6-month return-27.2%-16.1%6th lowest of 21
Distance from 52-week high-42.5%-37.9%8th lowest of 21
Revenue growth (TTM)+17.9%+5.4%2nd highest of 21
Operating margin-59.9%3.5%2nd lowest of 21
EV / Sales1.6×2.7×7th cheapest of 19
ROIC minus cost of capital-16.0 pp-1.6 pp4th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zhejiang Orient Gene Biotech 688298.SSChina$500M-27%+18%-60%1.6×n/an/a
Nanjing Vishee Medical Technology 688580.SSChina$499M-43%+7%24%5.3×20.1%+4.2%
medmix MEDX.SWSwitzerland$494M+11%-7%6%1.4×4.5%+5.0%
Assure Tech (Hangzhou) 688075.SSChina$508M-27%-9%-8%5.4×30.8%-18.6%
Anteris Technologies Global AVRUnited States$508M-40%+9%-4,880%125.0×n/an/a
Zhejiang Starry Pharmaceutical 603520.SSChina$491M-44%+9%3%2.2×n/an/a
Shofu 7979.TJapan$510M+32%+9%14%1.6×n/an/a
Guangdong Hybribio Biotech 300639.SZChina$511M-18%-7%4%3.9×0.4%-13.2%
Wuhan Easy Diagnosis Biomedicine 002932.SZChina$485M-14%-9%-51%n/an/an/a
Hangzhou Alltest Biotech 688606.SSChina$484M-20%0%13%1.3×-6.5%-4.3%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%1.5×6.0%-7.7%
Medprin Regenerative Medical Technologies 301033.SZChina$482M-14%+23%31%7.0×4.3%+24.4%
Guangdong Biolight Meditech 300246.SZChina$478M-35%+7%-8%3.1×55.3%-4.7%
CellaVision CEVI.STSweden$477M+64%+2%23%6.1×7.1%+10.0%
AngioDynamics ANGOUnited States$476M-4%+8%-6%1.4×n/an/a
WELL LEAD MEDICAL 603309.SSChina$473M-22%+1%15%2.0×-5.9%+7.7%
AVITA Medical RCELUnited States$529M+290%+17%-34%6.7×n/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%0.8×n/an/a
Jin Medical International ZJYLUnited States$532M+47%-14%2%26.5×n/an/a
Eiken Chemical 4549.TJapan$466M-20%+4%6%1.6×n/an/a

Questions

Which companies are Zhejiang Orient Gene Biotech's closest peers?
The cockpit's peer set: Nanjing Vishee Medical Technology (688580.SS), medmix (MEDX.SW), Assure Tech (Hangzhou) (688075.SS), Anteris Technologies Global (AVR), Zhejiang Starry Pharmaceutical (603520.SS), Shofu (7979.T), Guangdong Hybribio Biotech (300639.SZ), Wuhan Easy Diagnosis Biomedicine (002932.SZ).
Is Zhejiang Orient Gene Biotech expensive compared with its peers?
On ev / sales it trades at 1.6× against a peer median of 2.7×, 7th cheapest of 19 in its peer set.
How has Zhejiang Orient Gene Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -27.2% against -16.1% for the median peer; over one year -36.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.